微卫星不稳定性
彭布罗利珠单抗
生物标志物
药品
食品药品监督管理局
医学
癌症
药物开发
肿瘤科
内科学
癌症研究
药理学
免疫疗法
生物
微卫星
生物化学
等位基因
基因
作者
Steven J. Lemery,Lola A. Fashoyin‐Aje,Leigh Jessica Marcus,Sandra J. Casak,Julie A. Schneider,Marc Robert Theoret,Paul Gustav Kluetz,Richard Pazdur,Julia A. Beaver
标识
DOI:10.1146/annurev-cancerbio-060921-021828
摘要
In 2017 the FDA (US Food and Drug Administration) approved pembrolizumab, a programmed death 1 (PD-1) inhibitor, for the treatment of unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, regardless of tumor site or histology. This represented the first approval based on the identification of a biomarker and independent of tumor site. Although this approach may intuitively appear rational, tissue-agnostic drug development can be complicated by tumor-specific resistance mechanisms or other factors that can alter a drug's effect. Inherent with the tissue-agnostic approach is the fact that there may be residual uncertainty concerning a drug's effect in unstudied tumor types (e.g., at the time of approval). However, this approach may be the only available mechanism to support approval and provide access to a drug that is indicated for the treatment of patients with certain rare biomarker-positive cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI